| Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy: mechanisms and clinical trials X Chu, W Tian, Z Wang, J Zhang, R Zhou Molecular cancer 22 (1), 93, 2023 | 95 | 2023 |
| Cancer stem cells: Advances in knowledge and implications for cancer therapy X Chu, W Tian, J Ning, G Xiao, Y Zhou, Z Wang, Z Zhai, G Tanzhu, J Yang, ... Signal Transduction and Targeted Therapy 9 (1), 170, 2024 | 63 | 2024 |
| Chronic stress: impacts on tumor microenvironment and implications for anti-cancer treatments W Tian, Y Liu, C Cao, Y Zeng, Y Pan, X Liu, Y Peng, F Wu Frontiers in cell and developmental biology 9, 777018, 2021 | 40 | 2021 |
| Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer Y Zeng, D Yu, W Tian, F Wu Current opinion in oncology 34 (1), 54-65, 2022 | 37 | 2022 |
| Anti-angiogenic therapy in the treatment of non-small cell lung cancer W Tian, C Cao, L Shu, F Wu OncoTargets and therapy, 12113-12129, 2020 | 37 | 2020 |
| Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis S Wang, Y Li, Z Liu, W Tian, Y Zeng, J Liu, S Zhang, Y Peng, F Wu Lung Cancer 178, 47-56, 2023 | 19 | 2023 |
| Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis W Tian, X Chu, G Tanzhu, R Zhou Journal of Translational Medicine 21 (1), 244, 2023 | 11 | 2023 |
| The scheme, and regulative mechanism of pyroptosis, ferroptosis, and necroptosis in radiation injury J Ning, L Chen, Y Zeng, G Xiao, W Tian, Q Wu, J Tang, S He, G Tanzhu, ... International Journal of Biological Sciences 20 (5), 1871, 2024 | 10 | 2024 |
| Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States W Tian, L Niu, Z Wang, R Lu, G Xiao, F Deng, G Tanzhu, R Zhou Frontiers in Immunology 14, 1268070, 2023 | 6 | 2023 |
| Efficacy and safety of personalized optimal PD-(L) 1 combinations in advanced NSCLC: a network meta-analysis X Chu, W Tian, J Ning, R Zhou JNCI: Journal of the National Cancer Institute 116 (10), 1571-1586, 2024 | 4 | 2024 |
| Cost-effectiveness of tumor-treating fields plus standard therapy for advanced non-small cell lung cancer progressed after platinum-based therapy in the United States W Tian, J Ning, L Chen, Y Zeng, Y Shi, G Xiao, S He, G Tanzhu, R Zhou Frontiers in Pharmacology 15, 1333128, 2024 | 3 | 2024 |
| Corrigendum: Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments W Tian, Y Liu, C Cao, Y Zeng, Y Pan, X Liu, Y Peng, F Wu Frontiers in Cell and Developmental Biology 10, 865043, 2022 | 3 | 2022 |
| Adjuvant EGFR Tyrosine Kinase Inhibitors for Patients with Resected EGFR-Mutated Non-Small-Cell Lung Cancer: A Network Meta-Analysis W Tian, N Tan, J Ke, J Zou, X Liu, Y Pan, Y Zeng, Y Peng, F Wu Future Oncology 18 (21), 2695-2707, 2022 | 2 | 2022 |
| First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and … W Tian, L Niu, Y Shi, S Li, R Zhou Therapeutic Advances in Medical Oncology 16, 17588359241255613, 2024 | 1 | 2024 |
| Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer W Tian, L Niu, R Zhou, Z Wang, J Ning, R Lu, Y Shi, Z Tan Cancer Medicine 13 (16), e70083, 2024 | | 2024 |
| Chronic Stress: Impacts on Tumor Microenvironment and Implications for Anti-Cancer Treatments (vol 9, 777018, 2021) W Tian, Y Liu, C Cao, Y Zeng, Y Pan, X Liu, Y Peng, F Wu Frontiers in cell and developmental biology 10, 2022 | | 2022 |
| Subgroup-Level Network Meta-Analysis for the Efficacy of First-Line Immunotherapy-Based Treatments in Advanced Non-Small Cell Lung Cancer W Tian, C Cao, J Ke, N Tan, Y Cai, Y Zeng, Y Pan, X Liu, L Zhao, L Shu, ... | | 2021 |
| Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer. F Wu, W Tian, C Cao, J Ke, N Tan, Y Cai, Y Zeng, Y Pan, X Liu, L Zhao, ... Journal of Clinical Oncology 39 (15_suppl), 9064-9064, 2021 | | 2021 |
| Efficacy and Safety of Perioperative Immunotherapy for Non-Small Cell Lung Cancer: A Network Meta-Analysis S Wang, X Tian, Z Liu, Y Li, X Deng, W Tian, Y Zeng, Y Peng, W Xiao, ... Available at SSRN 4702386, 0 | | |
